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Abstract
Background: The rapid spread of the severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), and coronavirus disease 2019 (COVID-19), has caused more than 3.9 
million cases worldwide. Currently, there is great interest to assess venous thrombo-
sis prevalence, diagnosis, prevention, and management in patients with COVID-19.
Objectives: To determine the prevalence of venous thromboembolism (VTE) in criti-
cally ill patients with COVID-19, using lower limbs venous ultrasonography screening.
Methods: Beginning March 8, we enrolled 25 patients who were admitted to the in-
tensive care unit (ICU) with confirmed SARS-CoV-2 infections. The presence of lower 
extremity deep vein thrombosis (DVT) was systematically assessed by ultrasonogra-
phy between day 5 and 10 after admission. The data reported here are those available 
up to May 9, 2020.
Results: The mean (± standard deviation) age of the patients was 68 ± 11 years, and 
64% were men. No patients had a history of VTE. During the ICU stay, 8 patients 
(32%) had a VTE; 6 (24%) a proximal DVT, and 5 (20%) a pulmonary embolism. The 
rate of symptomatic VTE was 24%, while 8% of patients had screen-detected DVT. 
Only those patients with a documented VTE received a therapeutic anticoagulant 
regimen. As of May 9, 2020, 5 patients had died (20%), 2 remained in the ICU (8%), 
and 18 were discharged (72%).
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Essentials
• Initial reports suggest increased coagulation activity in patients with coronavirus disease 2019 (COVID-19).
• In critically ill patients, lower-extremity deep vein thrombosis (DVT) was systematically assessed by ultrasonography.
• The rate of symptomatic venous thromboembolism was 24%, while 8% of patients had screen-detected DVT.
• Early systematic screening for lower-limb DVT might be warranted in patients with COVID-19.
1  | INTRODUCTION
In December 2019, a novel severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) was discovered, causing more than 3.9 million 
confirmed cases of the coronavirus disease 2019 (COVID-19)1. Initial 
reports from China and Italy suggested a high mortality,2,3 especially in 
critically ill patients requiring invasive mechanical ventilation, of whom 
more than 80% died.3 Importantly, most of the patients with COVID-
19 (68%) had increased coagulation activity, and D-dimer concentra-
tions >1000 μg/L were associated with an increased risk of hospital 
death4. In recent retrospective studies, the prevalence of symptomatic 
venous thromboembolism (VTE) was 25%-27%,5,6 which might con-
tribute to the significant mortality rate. Compounding this problem, 
performance of repeated computed tomography pulmonary angiogra-
phy (CTPA) is not possible in the context of a pandemic COVID-19 out-
break and in overwhelmed intensive care units (ICUs).2 Altogether, this 
has led many centers to empirically increase the anticoagulant dosage. 
In the absence of supportive evidence for these practices, we evalu-
ated the role of systematic deep vein thrombosis (DVT) screening with 
lower-limb venous compression ultrasound (CUS) and the prevalence 
of VTE among critically ill patients with COVID-19.
2  | METHODS
2.1 | Study population, setting, and data collection
We included patients with laboratory-confirmed COVID-19 infec-
tion who were admitted to the Sion (Switzerland) hospital ICU for 
hypoxemic respiratory failure, between March 8 and April 4, 2020. 
None of the patients were excluded. The hospital was designed 
as the reference center for the state, and 50 ICU beds were made 
available. A confirmed case of COVID-19 was defined as a positive 
result on a reverse transcriptase–polymerase chain reaction assay 
of a specimen collected from a nasopharyngeal swab, sputum, or 
bronchial aspirate. Twenty-five adults (≥18 years of age) were identi-
fied from our institution There were no pregnant women or children 
admitted to our ICU during the study period. The study protocol 
was in accordance with the Declaration of Helsinki, and approved 
by the local ethics committee (2020-00856). Informed consent was 
waived. We collected demographic data, information on clinical 
symptoms or signs at presentation, and laboratory and radiologic 
results during the ICU stay, from each individual electronic medi-
cal record. All laboratory tests and radiologic assessments (including 
support from the Swiss National Science 
Foundation (SNSF PZ00P3-185927), the 
Leenaards, and the Novartis Foundation.
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Conclusions: In critically ill patients with SARS-CoV-2 infections, DVT screening at 
days 5-10 of admission yielded a 32% prevalence of VTE. Seventy-five percent of 
events occurred before screening. Earlier screening might be effective in optimizing 
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CT pulmonary angiography [CTPA]) were performed at the discre-
tion of the treating physician. As a screening test, lower-limb venous 
CUS was systematically performed in all patients by 2 independent 
vascular specialists, between days 5 and 10 after admission to the 
ICU.
2.2 | Study definitions
Coexisting conditions were ascertained from physician documenta-
tion. Acute respiratory distress syndrome was defined according to 
the Berlin definition.7 VTE events were defined as a pulmonary em-
bolism (PE) or a proximal lower-extremity DVT. PEs were diagnosed 
by CPTA, and DVTs by CUS. Upper-extremity DVT, catheter-related 
thrombosis, and arterial thrombosis were not recorded. Major and 
nonmajor bleeding were defined according to the ISTH criteria.8 
Disseminated intravascular coagulation scores were calculated using 
the ISTH scoring system.9
2.3 | Specimen collection and testing
Clinical specimens for COVID-19 diagnosis were tested with the 
assay based on the World Health Organization standard, which 
targets the SARS-CoV-2 E gene and RdRp gene.10 The systematic 
lower-limb CUS assessed proximal veins, from the common femoral 
veins down to the popliteal veins. The criterion for establishing the 
diagnosis of DVT was the lack of compressibility on B-mode ultra-
sound.11 The criterion for establishing the diagnosis of PE was the 
presence of an intraluminal filling defect on CTPA in a segmental 
or more proximal pulmonary artery.12 D-dimer levels were quan-
tified with an automated latex-enhanced quantitative immunotur-
bidimetric assay, the Innovance D-Dimer assay (Siemens Medical 
Solutions, Malvern, PA, USA), on the Behring Coagulation System 
analyzer.
2.4 | Statistical analysis
Descriptive statistics were used to report the data; results are re-
ported as medians and interquartile ranges (IQRs) or means and 
standard deviations, as appropriate. Categorical variables were 
summarized as numbers and percentages. No imputation was 




Of the 25 patients recruited, the mean (± standard deviation) 
patient age was 68 ± 11 years (range, 49-82); 64% were men 
(Table 1). No patients had a history of VTE. Median body mass 
index was (27.5 ± 4.6). Twenty-three (92%) patients needed me-
chanical ventilation, and 19 (76%) patients required hemodynamic 
support with norepinephrine for >12 hours. Fibrinogen (6.4 g/L; 
range, 4.5-7.2) and D-dimer (2071 μg/L; range, 953-3606) levels 
were high. A chest radiograph was obtained in all 25 patients, 
which showed bilateral infiltrates in all (100%). A CTPA scan was 
obtained in 7 patients (28%) on admission; all of the computed 
tomography scans showed bilateral ground glass opacities, and 
TA B L E  1   Baseline patient characteristics
Characteristic and clinical data on admission
Patients
(N = 25)




Body mass index, mean (SD)a  27.5 (4.6)
Coexisting disorders, n (%)
Hypertension 10 (40)
Cardiovascular disease 3 (12)
Diabetes mellitus 1 (4)
Chronic obstructive pulmonary disease 2 (8)
Obstructive sleep apnea 3 (12)
Asthma 1 (4)
Current or former tobacco smoker 6 (24)
Active malignancy 2 (8)
History of venous thromboembolism 0
Mean duration of symptoms before ICU 
admission, d (SD)
10 (3)
Laboratory data, median (IQR)
Fibrinogen, g/Lb  6.4 (4.5-7.2)
D-dimer, μg/Lc   2071 
(953-3606)
Creatinine, μmol/L 74 (64-93)




Chest radiography 25 (100)
Chest computed tomography 7 (28)
ICU therapies, n (%)
Invasive mechanical ventilation 23 (92)
Prone position 14 (56)
Vasopressors 19 (76)
Note: No patients had cerebrovascular disease, chronic kidney and liver 
disease, or human immunodeficiency virus infection.
aBody mass index is the weight in kilograms divided by the square of the 
height in meters. 
bData were available for 14 of the 25 patients. 
cData were available for 12 of the 25 patients. 
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1 showed multiple bilateral segmental PE (4%). Figure 1 provides 
representative images.
3.2 | Venous thromboembolism characteristics
All patients were prescribed a thromboprophylactic regimen, either 
with continuous intravenous heparin infusion (15 000 IU/24 h, or 
20 000 IU/24 h for patients >100 kg), or once-daily subcutaneous 
enoxaparin injections (40 mg, or 60 mg for patients >100 kg, Table 2) 
since the admission. Two patients (8%) were on chronic therapeutic 
anticoagulation for atrial fibrillation. During the ICU stay, one third 
(32%) of the patients suffered from a VTE, 6 (24%) a proximal DVT, 5 
(20%) PEs, and 3 (12%) had both. All PEs were diagnosed with CTPA 
in patients with a clinical suspicion. PE locations are described in 
Table 2. Subsegmental PE was not recorded. Two (8%) DVTs were 
diagnosed on CUS performed systematically in all patients between 
days 5 and 10. Three (12%) of the patients with DVT had already 
been diagnosed with PE, and 1 (4%) had lower-limb edema. Two 
patients could not undergo systemic CUS because of early death. 
Altogether, the rate of symptomatic VTE was 24%, while 8% of pa-
tients had screen-detected DVT.
Of the 6 patients with PE, 1 was administered systemic throm-
bolysis. All patients with documented VTE received a therapeutic 
anticoagulant treatment. The median time spent in the ICU before a 
symptomatic VTE event was 3 days (IQR, 2-7). During the ICU stay, no 
patient experienced major bleeding. As of May 9, 2020; 5 patients had 
died (20%), 2 remained in the ICU (8%), and 18 were discharged (72%).
4  | DISCUSSION
In this monocentric case series of 25 critically ill patients admitted 
to the ICU with COVID-19–related acute hypoxemic respiratory 
failure, we found a high rate of VTE events. Indeed, 8 of 25 (32%) 
patients had an objectively confirmed PE and/or lower-limb proxi-
mal DVT, despite adequate thromboprophylaxis. In contrast to most 
other studies,5,6 patients were systematically screened for lower-
limb DVT. Thus, this prevalence suggests the maximum DVT rate. 
Interestingly, the median time spent in the ICU before a symptomatic 
documented VTE was 3 days, with 75% of events occurring before 
screening at days 5-10. This suggests that screening should be per-
formed earlier, which might be effective in optimizing care in ICU 
patients with COVID-19.
Initial reports on COVID-19 reported abnormal coagulation ac-
tivity, reflected by elevated D-dimer concentrations. This was as-
sociated with an increased risk of in-hospital death4. These studies 
did not report the occurrence of PE and DVT.4,13,14 In 2 recent ret-
rospectives studies, the prevalence of venous thrombotic complica-
tions ranged between 25% and 27%, consistent with our findings. In 
these studies, CUS and CPTA were performed only when thrombotic 
complications were suspected. Moreover, patients did not receive 
thromboprophylaxis6 or it was not standardized.5 They also failed to 
describe hemorrhagic complications. It remains unknown whether 
this high rate of VTE is related to a COVID-19–specific hypercoag-
ulable state or if it results from the overall condition of these pa-
tients, with profound and prolonged sedation, prone positioning, 
and systemic inflammation. Under adequate thromboprophylaxis, 
F I G U R E  1   Chest radiograph and 
computed tomography (CT) images of a 
patient with coronavirus disease 2019 
and pulmonary embolism. (A, B) The chest 
radiograph (anteroposterior and lateral 
views) at admission shows bilateral hazy 
opacities in the lung. (C) Axial CT images 
demonstrate extensive ground glass 
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the rate of VTE in acutely ill ICU patients has been reported to be 
around 10%.15 However, data on a potentially higher VTE risk in the 
subgroup of severe acute respiratory syndrome patients is lacking. 
Postmortem examination of 8 patients infected with SARS-CoV-1 
identified pulmonary thromboembolism in 4 patients (50%). Three 
(38%) of these patients also had lower-extremity DVT.16 In another 
retrospective study of patients with influenza A (H1N1) virus pneu-
monia, 5 (36%) patients had PE on computed tomography scan 
examination.
The question of a causal effect between VTE and the high mor-
tality rate in these patients was raised, as well as the potential ben-
efit of an enhanced thromboprophylaxis regimen.17 Together with 
the low observed bleeding rates in these patients, this has led many 
centers to empirically increase anticoagulant dosing. However, these 
practices cannot be supported by available evidence. A prospective 
randomized open-label trial comparing 2 different dosing regimens 
of thromboprophylaxis versus therapeutic doses of anticoagulants 
in patients admitted to a medical ward or the ICU has just started in 
Switzerland (NCT04345848).
Another question, which remains still open, is the usefulness of 
systematic CUS screening for DVT. In our series, the rate of symp-
tomatic VTE was 24%, while 2 (8%) patients were diagnosed by 
systematic lower-limb CUS. Although this proportion (25%) of as-
ymptomatic proximal DVT among confirmed VTE events could sug-
gest the usefulness of systematic CUS, 2 points deserve comment. 
While the current mortality in our series (20%) was low compared to 
others,3,18 it is impossible to predict if the clinical evolution of these 
asymptomatic patients would differ if they had not been diagnosed 
with DVT and were not given anticoagulant treatment. Second, the 
small sample size of our study precludes any formal conclusion on 
the benefit of systematic DVT screening. In view of the paucity of 
data, current screening practices differ widely across ICU wards 
worldwide.
Our study has several limitations. First, because of our focus on 
the most severely affected ICU patients, the sample size is small. 
Second, the dose of prophylactic heparin administered was higher 
than current guidelines8 because of the perceived higher risk of VTE 
as discussed above.4,5,19 This was in accordance with current local 
expert consensus but might have reduced the incidence of VTE.
In conclusion, the prevalence of VTE is high (32%) among criti-
cally ill patients with COVID-19. VTE occurred early in course of the 
disease, with 75% of events identified before screening at days 5-10. 
Thus, early systematic lower-limb CUS might be more effective in 
optimizing care in ICU patients with COVID-19.
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